NDA 206947 · Eisai INC
Lenvima
Lenvatinib Mesylate · Oral · Kinase Inhibitor
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Feb 13, 2015
Approved uses
12
Original approval plus efficacy supplements
Registered trials
591
73 Phase 3, 146 recruiting
FAERS reports
33,515
29,421 serious, 4,564 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 14, 2026.
LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with belzutifan, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma In combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-authorized test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 ) 1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). 1.2 Renal Cell Carcinoma LENVIMA, in combination with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph, is indicated for the first-line treatment of adult patients with...
Mechanism: Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet derived growth factor receptor alpha (PDGFRA), KIT, and RET. Lenvatinib also exhibited antiproliferative activity in hepatocellular carcinoma cell lines dependent on...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 24, 2026 Supplement 35 · Efficacy OrphanLetterLabel
- Jan 29, 2025 Supplement 33 · Efficacy · priority review OrphanLabelLetter
- Jun 7, 2024 Supplement 31 · Efficacy OrphanLabelLetter
- Apr 3, 2024 Supplement 30 · Efficacy · priority review OrphanLabelLetter
- Oct 23, 2023 Supplement 28 · Efficacy OrphanLetterLabel
- Dec 19, 2021 Supplement 21 · Efficacy LetterLabel
- Aug 10, 2021 Supplement 19 · Efficacy · priority review Breakthrough therapyLabelLetter
- Jul 21, 2021 Supplement 20 · Efficacy · priority review LabelLetter
- Sep 17, 2019 Supplement 11 · Efficacy · priority review Breakthrough therapyLabelLetter
- Aug 15, 2018 Supplement 7 · Efficacy OrphanLabelLetter
- May 13, 2016 Supplement 3 · Efficacy · priority review Breakthrough therapyLabelLetter
- Feb 13, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewLabelSummary Review
2 products under this application
- LENVIMA · LENVATINIB MESYLATE EQ 4MG BASE · CAPSULE, ORAL · Prescription
- LENVIMA · LENVATINIB MESYLATE EQ 10MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Lenvatinib" as an intervention, any sponsor and status, largest first.
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03486873 · 3,500 participants (planned) · Start Aug 21, 2018 · Primary completion Aug 4, 2043
Drug: Pembrolizumab; Standard of Care (SOC) and 5 more · For: Solid Tumors; Hematologic Malignancies
Sites: Tucson, Arizona; Bakersfield, California; Fresno, California · 782 sites in all
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04736706 · 1,688 participants · Start Apr 14, 2021 · Primary completion Feb 4, 2026
Drug: Pembrolizumab; Belzutifan and 2 more · For: Carcinoma, Renal Cell
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 262 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- CARE1 Pragmatic Clinical TrialPivotal-lookingRecruiting
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT06364631 · 1,250 participants (planned) · Start Apr 12, 2024 · Primary completion May 5, 2032
Drug: Nivolumab; Ipilimumab and 4 more · For: Metastatic Kidney Cancer; Metastatic Kidney Carcinoma
Sites: Vienna, Austria; Brno, Czechia; Hradec Králové, Czechia · 46 sites in all
- Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02861573 · 1,200 participants (planned) · Start Nov 17, 2016 · Primary completion Oct 22, 2027
Drug: Pembrolizumab 200 mg; Olaparib 400 mg and 10 more · For: Metastatic Castration-Resistant Prostate Cancer
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaPivotal-lookingActive, not recruiting
Eisai Inc.Eisai
NCT02811861 · 1,069 participants · Start Oct 13, 2016 · Primary completion Aug 28, 2020
Drug: Lenvatinib; Everolimus and 2 more · For: Renal Cell Carcinoma
Sites: Stanford, California; Boca Raton, Florida; Fort Myers, Florida · 183 sites in all
- A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular CarcinomaPivotal-lookingCompleted
Eisai LimitedEisai
NCT01761266 · 954 participants · Start Mar 1, 2013 · Primary completion Nov 13, 2016
Drug: Lenvatinib; Sorafenib · For: Hepatocellular Carcinoma (HCC)
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 186 sites in all
- Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04662710 · 895 participants · Start Dec 30, 2020 · Primary completion Oct 29, 2024
Drug: Pembrolizumab; Lenvatinib and 4 more · For: Advanced/Metastatic Gastroesophageal Adenocarcinoma
Sites: Los Angeles, California; Washington D.C., District of Columbia; Louisville, Kentucky · 177 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea4,243
- hypertension3,829
- fatigue3,425
- decreased appetite3,169
- malignant neoplasm progression2,570
- nausea2,531
- blood pressure increased2,189
- vomiting2,044
- asthenia1,661
- dehydration1,548
- weight decreased1,474
- malaise1,358
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 4 |
| 2015 | 377 |
| 2016 | 752 |
| 2017 | 1,055 |
| 2018 | 2,284 |
| 2019 | 2,998 |
| 2020 | 2,860 |
| 2021 | 2,880 |
| 2022 | 4,244 |
| 2023 | 5,451 |
| 2024 | 3,810 |
| 2025 | 3,982 |
| 2026 | 2,815 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lenvima (Lenvatinib Mesylate)
2024 spending
$876M
Beneficiaries
8,450
37,139 claims
Per beneficiary
$103,626
$491.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $367,767,779 |
| 2021 | $452,132,406 |
| 2022 | $625,976,421 |
| 2023 | $778,834,824 |
| 2024 | $875,642,919 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M, Finn RS, Qin S, et al. · Lancet 2018 · Clinical Trial, Phase III, Comparative Study
- Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Multicenter Study
- Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
Shi GM, Huang XY, Liang F, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
Yau T, Galle PR, Decaens T, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M, Tahara M, Wirth LJ, et al. · N Engl J Med 2015 · Clinical Trial, Phase III, Comparative Study
Sponsor: Eisai
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.